The new market report titled “Opportunities in the RNA Therapeutics Market”, published by Roots Analysis is one of the most sought-after solutions for investors operating in the RNA therapeutics market.
The report will help investors stay updated with the latest market trends and opportunities associated with the RNA therapeutics market. The report comes with a concise summary of the details regarding the historical market data, current market trends, future growth prospects, innovator and product landscape, company health indexing, value proposition analysis, company competitiveness, funding and investment, financial analysis of public ventures, business risk analysis, returns on investment and key acquisition targets, as well as the emerging market trends and opportunities in RNA therapeutics market. The opportunities in the RNA therapeutics market are anticipated to expand significantly.
However, the latest report is mainly intended for business leaders, experts, thought leaders, investors, start-ups and growth stage firms interested in RNA Therapeutics business space and is available in the form of PDF and spreadsheet.
Investor Series: Opportunities in the RNA Therapeutics Market:
Investor Series Scope and Market Size:
The report provides detailed information on the RNA therapeutics market, covering the core and peripheral RNA therapeutics solutions. It offers a technical and financial perspective on how the RNA therapeutics market opportunities is likely to evolve, in terms of future business success, over the coming decade. The RNA therapeutics market is broadly segmented on the basis of type of solution, type of therapy, therapeutic area and geographical regions. The segmental growth helps the investors, firms, business leaders to get a lucid picture of the niche pockets of growth, as well as the strategies deployed by the market players to drive the growth of these segments. This section of the report helps them understand and determine the core application areas and the differences between the target markets. The report scrutinizes the RNA therapeutics market in terms of market size & volume and significant information pertaining to product bifurcation and RNA therapeutics solutions overview.
Key Market Contenders:
This particular section of the RNA therapeutics market report covers all the necessary details of the RNA therapeutics’ solutions developed by players operating in the RNA therapeutics market. The report goes on to elucidate a quantitative perspective on the relative health of the different innovator companies and an assessment of the various solutions, offered by the companies developing DTx solutions, featuring analysis based on number and types of products, and an informed perspective on the value of the offerings based on multiple relevant aspects.
Information on the funding and investment activity that has taken place in this domain since 2011 has also been included in this report. Moreover, the exhaustive report presents financing category-wise trends, describing the relative maturity of the innovator companies. Further, RNA therapeutics market features a list of the leading RNA therapeutics investors , based on their participation in financing activity in this industry segment. It also covers an elaborate review of the overall RNA therapeutics market from a financial perspective, including detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of the publicly listed companies.
This section of RNA therapeutics market report focusing on the competitive terrain of the RNA therapeutics market endows the reader with every significant detail and information about the leading competitors on the market. The report provides a key acquisition targets analysis, highlighting some of the promising early-to-mid stage business ventures around which there is likely to be interest for future acquisitions / mergers and also includes the case study of instances where investors have exited various RNA therapeutics related ventures, offering insights on return on investments made. Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the RNA therapeutics market.
Section covered in RNA therapeutics market report:
Section 01: Need for RNA Therapeutics and Innovators Landscape
Section 02: Analysis of Investments
Section 03: Financial Analysis and Assessment of Business Risks
Section 04: Market Forecast and Opportunity Analysis
Section 05: Analysis of Returns on Investment and Key Acquisition Targets
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/opportunities-in-RNA-therapeutics-market.html
You may also be interested in the following titles:
Oral Solid Dosage Manufacturing Market
Lipid Nanoparticles in Drug Delivery
You may also like to learn what our experts are sharing in Roots educational series:
Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders
4D Bioprinting Market: Key Trends
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#RNATherapeuticsInvestorSeries #RNATherapeuticsMarket #RNAtherapeuticsmarketopportunities #RNAtherapeuticsinvestors #RNAtherapeuticsfunding
The new market report titled “Opportunities in the Digital Therapeutics Market”, published by Roots Analysis is one of the most sought-after solutions for investors operating in the Digital Therapeutics Market.
The report will help investors stay updated with the latest market trends and opportunities associated with the Digital Therapeutics Market. The report comes with a concise summary of the details regarding the historical market data, current market trends, future growth prospects, innovator and product landscape, company health indexing, value proposition analysis, company competitiveness, funding and investment, financial analysis of public ventures, business risk analysis, returns on investment and key acquisition targets, as well as the emerging market trends and opportunities in Digital Therapeutics Market. The opportunities in the Digital Therapeutics Market are anticipated to expand significantly.
The latest report is mainly intended for business leaders, experts, thought leaders, investors, start-ups and growth stage firms interested in Digital Therapeutics business space and is available in the form of PDF and spreadsheet.
Investor Series: Opportunities in the Digital Therapeutics Market:
Investor Series Scope and Market Size:
The report provides detailed information on the Digital Therapeutics Market, covering the core and peripheral Digital Therapeutics solutions. It offers a technical and financial perspective on how the Digital Therapeutics Market opportunities is likely to evolve, in terms of future business success, over the coming decade. The Digital Therapeutics Market is broadly segmented on the basis of type of solution, type of therapy, therapeutic area and geographical regions. The segmental growth helps the investors, firms, business leaders to get a lucid picture of the niche pockets of growth, as well as the strategies deployed by the market players to drive the growth of these segments. This section of the report helps them understand and determine the core application areas and the differences between the target markets. The report scrutinizes the Digital Therapeutics Market in terms of market size & volume and significant information pertaining to product bifurcation and Digital Therapeutics solutions overview.
Key Market Contenders:
This particular section of the Digital Therapeutics Market report covers all the necessary details of the Digital Therapeutics’ solutions developed by players operating in the Digital Therapeutics Market. The report goes on to elucidate a quantitative perspective on the relative health of the different innovator companies and an assessment of the various solutions, offered by the companies developing DTx solutions, featuring analysis based on number and types of products, and an informed perspective on the value of the offerings based on multiple relevant aspects.
Information on the funding and investment activity that has taken place in this domain since 2011 has also been included in this report. Moreover, the exhaustive report presents financing category-wise trends, describing the relative maturity of the innovator companies. Further, Digital Therapeutics Market features a list of the leading Digital Therapeutics investors , based on their participation in financing activity in this industry segment. It also covers an elaborate review of the overall Digital Therapeutics Market from a financial perspective, including detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of the publicly listed companies.
This section of Digital Therapeutics Market report focusing on the competitive terrain of the Digital Therapeutics Market endows the reader with every significant detail and information about the leading competitors on the market. The report provides a key acquisition targets analysis, highlighting some of the promising early-to-mid stage business ventures around which there is likely to be interest for future acquisitions / mergers and also includes the case study of instances where investors have exited various Digital Therapeutics related ventures, offering insights on return on investments made. Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the Digital Therapeutics Market.
Section covered in Digital Therapeutics Market report:
Section 01: Need for Digital Therapeutics and Innovators Landscape
Section 02: Analysis of Investments
Section 03: Financial Analysis and Assessment of Business Risks
Section 04: Market Forecast and Opportunity Analysis
Section 05: Analysis of Returns on Investment and Key Acquisition Targets
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/opportunities-in-digital-therapeutics-market.html
You may also be interested in the following titles:
Oral Solid Dosage Manufacturing Market
Lipid Nanoparticles in Drug Delivery
You may also like to learn what our experts are sharing in Roots educational series:
Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders
4D Bioprinting Market: Key Trends
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#DigitalTherapeuticsInvestorSeries #DigitalTherapeuticsMarket #Digitalhealthfunding #DigitalHealthInvestment #Digitalhealthfunds
Over time, significant strides have been made to carry out research to explore the benefits of artificial intelligence.
Further, several AI technologies are being investigated for the early treatment and diagnosis of cancer. Overall, this domain is anticipated to gain significant traction, in the foreseen future. The AI in oncology market is dominated by companies based in North America; of these majority were established post 2010. The financial opportunity within the Artificial Intelligence in Oncology market has been analyzed across the following segments:
Type of Cancer
Solid Malignancies
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Brain Tumor
Others
Type of End-User
Hospitals
Pharma Companies
Research Institutes
Others
Key Geographical Regions
North America
Europe
Asia Pacific
Rest of the World
The Artificial Intelligence in Oncology Market, 2022-2035, report features the following companies, which we identified to be key players in this domain:
Ibex Medical Analytics
Niramai
Optellum
Tempus Labs
Paige
Kheiron Medical Technologies
Table of Contents
-
Preface
-
Executive Summary
-
Introduction
-
Market Overview
-
Company Profiles
-
Company Competitiveness Analysis
-
Patent Analysis
-
Partnerships
-
Funding and Investment Analysis
-
Blue Ocean Strategy: A strategic guide for start-ups to enter into highly competitive market
-
Market Forecast and Opportunity Analysis
-
Conclusion
-
Executive Insights
-
Appendix 1: Tabulated Data
-
Appendix 2: List of Companies and Organizations
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/ai-in-oncology-market.html
You may also be interested in the following titles:
Oral Proteins and Peptides Market
Deep Learning in Drug Discovery Market and Deep Learning in Diagnostics Market
You may also like to learn what our experts are sharing in Roots educational series:
Liposomes Development: Service Providers Landscape
mRNA Synthesis: Manufacturing Process of Modern Revolutionary Molecule
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#ArtificialIntelligenceinOncologyMarket #ArtificialIntelligenceinOncologyMarketGrowth #aiinoncology #oncologicaldisorders #artificalintelligenceincancer
Roots Analysis has announced the addition of “Bacteriophage Therapeutics Market, 2022-2035” report to its list of offerings.
Key Market Insights
Over 100 bacteriophage therapeutics have either been marketed / are being developed by various well-established and small firms; majority of these therapeutics are being evaluated for the treatment of infectious diseases
Around 50% of the pipeline candidates are currently under clinical phase of development; of these, close to 50% are designed for oral and topical administration
Multiple clinical studies, evaluating various types of bacteriophage therapeutics among more than 3,000 patients across different centers / hospitals, have been registered worldwide
Over the years, the intellectual capital related to bacteriophage therapeutics has grown at a significant pace, with several patents being filed by both industry and non-industry players
A notable increase in published scientific literature related to bacterio-phage therapeutics has been observed over the years, demonstrating the growing interest in this domain
Various organizations have extended financial support to aid the ongoing research for bacteriophage therapies; currently, the focus, in terms of funds disbursed, is on clinical investigation of bacteriophage therapeutics
Several investors, having realized the benefits and future opportunity, have invested over USD 1 billion since 2017
The rising interest of stakeholders is also reflected by the number of partnerships signed in the recent past, involving players located in different geographical regions
Our proprietary start-up health indexing analysis confirms the presence of several new entrants that claim to possess the required capabilities for developing bacteriophage therapeutics
The market is anticipated to grow at a CAGR of ~10% till 2035; the forecasted opportunity is likely to be distributed across different therapeutic areas, routes of administration, and geographical regions
Table of Content
-
PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
-
EXECUTIVE SUMMARY -
INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Bacteriophages
3.3. Biology of Bacteriophages
3.4. Introduction to Bacteriophage Therapy
3.5. Applications of Bacteriophage Therapy
3.6. Advantages of Bacteriophage Therapy
3.7. Limitations of Bacteriophage Therapy
3.8. Conclusion
-
BACTERIOPHAGE THERAPEUTICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Bacteriophage Therapeutics: Drug Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Therapeutic Area
4.2.3. Analysis by Phase of Development and Therapeutic Area
4.2.4. Analysis by Targeted Bacterial Strain
4.2.5. Analysis by Target Disease Indication
4.2.6. Analysis by Type of Therapy
4.2.7. Analysis by Route of Administration
4.3. Information on Bacteriophage Related Technologies
-
BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE
5.1. Chapter Overview
5.2. Bacteriophage Therapeutics: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Leading Developers: Analysis by Number of Bacteriophage Therapeutics
-
COMPANY AND DRUG PROFILES
6.1. Chapter Overview
6.2. Eliava BioPreparations
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Pipeline Overview
6.2.3.1. Pyo Bacteriophage
6.2.3.2. Intesti Bacteriophage
6.2.3.3. SES Bacteriophage
6.2.3.4. Staphylococcal Bacteriophage
6.2.3.5. Fersisi Bacteriophage
6.2.3.6. Enko Bacteriophage
6.2.4. Recent Developments and Future Outlook
6.3. Micreos
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Pipeline Overview
6.3.3.1. PhageGuard Listex
6.3.3.2. PhageGuard S
6.3.3.3. PhageGuard E
6.3.4. Recent Developments and Future Outlook
6.4. NPO Microgen
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Pipeline Overview
6.4.3.1. E. coli-Proteus Bacteriophage
6.4.3.2. Streptococcus Bacteriophage
6.4.3.3. Complex Pyobacteriophage
6.4.3.4. Klebsiella Purified Polyvalent Bacteriophage
6.4.3.5. Sextaphag
6.4.3.6. Dysentery Bacteriophage
6.4.3.7. Intesti
6.4.4. Recent Developments and Future Outlook
6.5. ContraFect
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Pipeline Overview
6.5.3.1. Exebacase (CF-301)
6.5.3.2. CF-296
6.5.3.3. CF-370
6.5.3.4. Gram-Negative Lysins
6.5.3.5. Amurins
6.5.4. Recent Developments and Future Outlook
6.6. Adaptive Phage Therapeutics
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Pipeline Overview
6.6.3.1. Bacteriophage Therapeutics
6.6.4. Recent Developments and Future Outlook
6.7. Phagelux
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Pipeline Overview
6.7.3.1. PGX-0100
6.7.3.2. BactelideTM
6.7.3.3. BactelideTM
6.7.4. Recent Developments and Future Outlook
6.8. Pherecydes Pharma
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Pipeline Overview
6.8.3.1. Bacteriophage Therapeutics
6.8.4. Recent Developments and Future Outlook
-
CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Bacteriophage Therapeutics Market: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
7.3.3. Analysis by Trial Status
7.3.4. Analysis by Trial Phase and Enrolled Patient Population
7.3.5. Analysis by Study Design
7.3.6. Analysis by Type of Sponsor / Collaborator
7.3.7. Most Active Players: Analysis by Number of Registered Trials
7.3.8. Regional Analysis
7.3.8.1. Analysis by Number of Registered Trials
7.3.8.2. Analysis by Enrolled Patient Population
-
PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Bacteriophage Therapeutics: Patent Analysis
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Patent Application Year
8.3.3. Analysis by Annual Number of Granted Patent(s) and Patent Application(s)
8.3.4. Analysis by Geography
8.3.5. Analysis by CPC Symbols
8.3.6. Analysis by Type of Applicant
8.3.7. Leading Players: Analysis by Number of Patents
8.4. Bacteriophage Therapeutics: Patent Benchmarking
8.4.1. Analysis by Patent Characteristics
8.5. Bacteriophage Therapeutics: Patent Valuation
8.6. List of Leading Patents
-
PUBLICATION BENCHMARKING ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.2.1. Analysis by Year of Publication
9.2.2. Analysis by Type of Article
9.2.3. Analysis by Popular Keywords
9.2.4. Popular Publishers: Analysis by Number of Publications
9.2.5. Popular Journals: Analysis by Number of Publications
9.2.6. Popular Journals: Analysis by Journal Impact Factor
9.2.7. Publications: Timeline Analysi
9.3. Publication Benchmarking
-
ACADEMIC GRANTS ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Bacteriophage Therapeutics: Academic Grant Analysis
10.3.1. Analysis by Year of Grant Award
10.3.2. Analysis by Amount Awarded
10.3.3. Analysis by Administering Institute Center
10.3.4. Analysis by Support Period
10.3.5. Analysis by Funding Institute Center and Support Period
10.3.6. Analysis by Type of Grant Application
10.3.7. Analysis by Purpose of Grant Award
10.3.8. Analysis by Activity Code
10.3.9. Word Cloud Analysis: Emerging Focus Areas
10.3.10. Analysis by Study Section Involved
10.3.11. Popular NIH Departments: Analysis by Number of Grants
10.3.12. Analysis by Type of Recipient Organization
10.3.13. Prominent Program Officers: Analysis by Number of Grants
10.3.14. Popular Recipient Organizations: Analysis by Number of Grants
10.3.15. Regional Distribution of Recipient Organizations
-
FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Bacteriophage Therapeutics Market: List of Funding and Investments
11.3.1. Analysis by Year of Investment
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Most Active Players: Analysis by Number of Funding Rounds and Amount Raised
11.3.5. Investors Analysis
11.3.6. Regional Distribution by Amount Invested
11.4. Concluding Remarks
-
PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Bacteriophage Therapeutics: List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year of Partnership and Type of Partner
12.3.4. Analysis by Therapeutic Area
12.3.5. Analysis by Application Area
12.3.6. Most Active Players: Analysis by Number of Partnerships
12.3.7. Regional Analysis
12.3.7.1. Intercontinental and Intracontinental Agreements
-
START-UP HEALTH INDEXING
13.1. Chapter Overview
13.2. Bacteriophage Therapeutics Developers: Start-ups
13.2.1. Analysis by Location of Headquarters
13.3. Benchmarking of Start-ups
13.3.1. Analysis by Pipeline Strength
13.3.2. Analysis by Pipeline Maturity
13.3.3. Analysis by Indication Diversity
13.3.4. Analysis by Number of Patents
13.3.5. Analysis by Funding Amount
13.3.6. Analysis by Partnership Activity
13.3.7. Start-ups Health Indexing: Roots Analysis Perspective
-
MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Assumptions
14.3. Forecast Methodology
14.4. Global Bacteriophage Therapeutics Market, 2022-2035
14.4. 1. Bacteriophage Therapeutics Market, 2022-2035: Distribution by Therapeutic Area
14.4.1.1. Bacteriophage Therapeutics Market for Gastrointestinal Infectious, 2022-2035
14.4.1.2. Bacteriophage Therapeutics Market for Bacterial Dysentery, 2022-2035
14.4.1.3. Bacteriophage Therapeutics Market for Multiple Infections, 2022-2035
14.4. 2. Bacteriophage Therapeutics Market, 2022-2035: Distribution by Route of Administration
14.5.2.1. Bacteriophage Therapeutics Market for Oral Therapies, 2022-2035
14.5.2.2. Bacteriophage Therapeutics Market for Rectal Therapies, 2022-2035
14.5.2.3. Bacteriophage Therapeutics Market for Intravesical Therapies, 2022-2035
14.5.2.4. Bacteriophage Therapeutics Market for Topical Therapies, 2022-2035
14.4. 3. Bacteriophage Therapeutics Market, 2022-2035: Distribution by Geography
14.6.3.1. Bacteriophage Therapeutics in North America, 2022-2035
14.6.3.2. Bacteriophage Therapeutics in Europe, 2022-2035
-
CONCLUSION -
EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Rime Bioinformatics
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Antoine Culot, Chief Executive Officer
16.3. BiomX
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Iddo Weiner, Senior Director, Head of Data-Science
16.4. Hospices Civils De Lyon
16.4.1. Organization Snapshot
16.4.2. Interview Transcript: Mathieu Medina, Project Leader
16.5. Independent Consultant
16.5.1. Interview Transcript: Mohammadreza Azizkhani, Scientific Researcher
-
APPENDIX I: TABULATED DATA -
APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html
You may also be interested in the following titles:
Lab Automation Market
Cannabis Testing Market
You may also like to learn what our experts are sharing in Roots educational series:
T-cell Immunotherapies: The Future of Modern Cancer Treatments
Monkeypox: Disease Overview, Transmission and Diagnosis
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#Bacteriophagetherapeuticsmarket #Bacteriophagetherapeuticsmarketsize #bacteriophage #phage #bacteriophagetherapy
The popularity of 3D printing technology within the dental industry can be attributed to its ability to print high quality / accurate dental products, including crowns, bridges, dentures, dental implants and surgical guides.
Driven by the overall growth of the additive manufacturing (3D printing) industry, and wide adoption of 3D printers in the dental sector, the dental 3D printing market is anticipated to witness a steady growth in the foreseen future.
The financial opportunity within the SMOs market has been analyzed across the following segments:
Type of Printing Technology
VAT Polymerization Technology
Powder Bed Fusion Technology
Polyjet Technology
Metal Extrusion Technology
Other Technologies
Application Area
Prosthodontics
Orthodontics
Dental Implants
Other Applications
Type of Printing Material
Resins
Plastics
Metals
Metals
Other Material
Key Geographical Regions
North America
Europe
Asia-Pacific
Latin America
Middle East and North Africa
Rest of the World
The Dental 3D Printing Market, 2022 – 2035 report studies dental 3D printing manufacturers in detail and features the following companies, which we identified to be key players in this domain:
3D Systems
Asiga
BEGO
Carbon
Digital Wax Systems (DWS)
Formlabs
Prodways
Rapid Shape
SprintRay
Stratasys
Table of Contents
-
Preface
-
Executive Summary
-
Introduction
-
Market Landscape
-
Product Competitive Analysis
-
Company Profiles
-
Partnerships and Collaborations
-
Patent Analysis
-
Bowman Clock Pricing
-
Market Forecast and Opportunity Analysis
-
Concluding Remarks
-
Executive Insights
-
Appendix 1: Tabulated Data
-
Appendix 2: List of Companies And Organizations
Get more details on the Dental 3D Printing Market report https://www.rootsanalysis.com/reports/dental-3d-printing-market.html
You may also be interested in the following titles:
Digital Therapeutics Market
Global TIL Therapies Market
You may also like to learn what our experts are sharing in Roots educational series:
Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders
4D Bioprinting Market: Key Trends
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#Dental3DPrintingmarket #Dental3DPrintingmarketsize #Dental3dPrinterManufacturers #3DDentalPrinterManufacturers #Dental3DPrinterManufacturersforDentalImplants
The new market report titled ‘CRISPR Technologies: Intellectual Property Landscape,’ published by Roots Analysis features an extensive study of some of the key historical and contemporary intellectual property (IP) documents (featuring granted patents, patent applications and other documents), describing the various types of CRISPR Technologies.
The insights generated in this report have been presented across two deliverables, namely a MS Excel workbook and a MS PowerPoint deck, summarizing the ongoing trend in this domain.
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/crispr-technologies-ip-landscape.html
Main Chapters in the CRISPR Technologies Intellectual Property Landscape Report
Overall Intellectual Property Landscape
An analytical perspective of the various patents and affiliated IP documents that have been published related to CRISPR Technologies, since 2000. An in-depth analysis of published IP documents, representing unique patent families across various global jurisdictions, featuring insightful inferences related to both historical and recent R&D trends within this domain.
Popular / Relevant Prior Art Search Expressions
An examination of IP literature, shortlisting key words and phrases used to describe CRISPR Technologies. The analysis also includes details on the historical use of the aforementioned terms across different IP filings, key affiliated terms and other related trends.
Patent Valuation Analysis
Competitive benchmarking and valuation analysis of the key members of unique patent families captured in the report, taking into consideration important parameters of the patent application.
Patentability and Freedom to Operate
A systematic and Roots Proprietary approach to identify relevant areas of innovation by analyzing published IP documents, by defining the uniqueness of patented / patent pending innovations, in order to assess the scope of patentability in this domain, and pinpoint jurisdictions wherein new and / or modified claims may be filed without infringing on existing IP.
Analysis of Patent Applications and Granted CRISPR Technologies Patents
A detailed summary of the various patent applications and granted patents across different jurisdictions and their relative value in the IP ecosystem. The analysis classified the intellectual capital in terms of type of innovation and the innovation related to CRISPR Technologies, thereby offering the means to identify active arenas of research and assess innovation-specific IP filing trends.
Pockets of Innovation and White Spaces
An insightful analysis of the various CPC codes used in published IP literature and their affiliated families, offering the means to identify historical and existing pockets of innovation, the analysis also features a discussion on prevalent white spaces.
Claim Analysis
One of the objectives of the report was to analyze and summarize key inferences from the independent claims mentioned in granted, active patents in the dataset. Using a systematic segregation approach, we have analyzed trends associated with the preamble, type of patent, type of claim and other key elements of a claim.
Key Companies Profiled
• 10x Genomics
• 22nd Century Group
• 64x Bio
• Aadigen
• Aarhus University
You may also be interested in the following titles:
Quantum Computing in Drug Discovery Services Market
Viral Clearance and Viral Testing Services Market
You may also like to learn what our experts are sharing in Roots educational series:
Is Blue Ocean Strategy The Silver Bullet For Emerging Teleradiology Players to Achieve A Breakthrough In This Highly Competitive Market?
Medical Device Coatings and Modification Technologies
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#CASTechnology #DNASequences #CRISPRTechnologiesMarket #CRISPRIP #CRISPRPatents
The new market report titled “Opportunities in the Artificial Intelligence in Drug Discovery Market”, published by Roots Analysis is one of the most sought-after solutions for investors operating in the Artificial Intelligence in Drug Discovery market.
The report will help investors stay updated with the latest market trends and opportunities associated with the Artificial Intelligence in Drug Discovery market. The report comes with a concise summary of the details regarding the historical market data, current market trends, future growth prospects, innovator and product landscape, company health indexing, value proposition analysis, company competitiveness, funding and investment, financial analysis of public ventures, business risk analysis, returns on investment and key acquisition targets, as well as the emerging market trends and opportunities in Artificial Intelligence in Drug Discovery market. The opportunities in the Artificial Intelligence in Drug Discovery market are anticipated to expand significantly.
However, the latest report is mainly intended for business leaders, experts, thought leaders, investors, start-ups and growth stage firms interested in Artificial Intelligence in Drug Discovery business space and is available in the form of PDF and spreadsheet.
Investor Series: Opportunities in the Artificial Intelligence in Drug Discovery Market:
Investor Series Scope and Market Size:
The report provides detailed information on the Artificial Intelligence in Drug Discovery market, covering the core and peripheral Artificial Intelligence in Drug Discovery solutions. It offers a technical and financial perspective on how the Artificial Intelligence in Drug Discovery market opportunities is likely to evolve, in terms of future business success, over the coming decade. The Artificial Intelligence in Drug Discovery market is broadly segmented on the basis of type of solution, type of therapy, therapeutic area and geographical regions. The segmental growth helps the investors, firms, business leaders to get a lucid picture of the niche pockets of growth, as well as the strategies deployed by the market players to drive the growth of these segments. This section of the report helps them understand and determine the core application areas and the differences between the target markets. The report scrutinizes the Artificial Intelligence in Drug Discovery market in terms of market size & volume and significant information pertaining to product bifurcation and Artificial Intelligence in Drug Discovery solutions overview.
Key Market Contenders:
This particular section of the Artificial Intelligence in Drug Discovery market report covers all the necessary details of the Artificial Intelligence in Drug Discovery’ solutions developed by players operating in the Artificial Intelligence in Drug Discovery market. The report goes on to elucidate a quantitative perspective on the relative health of the different innovator companies and an assessment of the various solutions, offered by the companies developing DTx solutions, featuring analysis based on number and types of products, and an informed perspective on the value of the offerings based on multiple relevant aspects.
Information on the funding and investment activity that has taken place in this domain since 2011 has also been included in this report. Moreover, the exhaustive report presents financing category-wise trends, describing the relative maturity of the innovator companies. Further, Artificial Intelligence in Drug Discovery market features a list of the leading Artificial Intelligence in Drug Discovery investors, based on their participation in financing activity in this industry segment. It also covers an elaborate review of the overall Artificial Intelligence in Drug Discovery market from a financial perspective, including detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of the publicly listed companies.
This section of Artificial Intelligence in Drug Discovery market report focusing on the competitive terrain of the Artificial Intelligence in Drug Discovery market endows the reader with every significant detail and information about the leading competitors on the market. The report provides a key acquisition targets analysis, highlighting some of the promising early-to-mid stage business ventures around which there is likely to be interest for future acquisitions / mergers and also includes the case study of instances where investors have exited various Artificial Intelligence in Drug Discovery related ventures, offering insights on return on investments made. Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the Artificial Intelligence in Drug Discovery market.
Section covered in Artificial Intelligence in Drug Discovery market report:
Section 01: Need for Artificial Intelligence in Drug Discovery and Innovators Landscape
Section 02: Analysis of Investments
Section 03: Financial Analysis and Assessment of Business Risks
Section 04: Market Forecast and Opportunity Analysis
Section 05: Analysis of Returns on Investment and Key Acquisition Targets
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/ai-in-drug-discovery-investor-series.html
You may also be interested in the following titles:
4D Bioprinting Market
Non-Viral / Intracellular Drug Delivery Systems Market
You may also like to learn what our experts are sharing in Roots educational series:
Smart pharmaceutical and healthcare labels: Lets trace medicines from its origin
Introduction To Exosome Therapeutics
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#OpportunitiesinArtificialIntelligenceinDrugDiscoverymarket #ArtificialIntelligenceinDrugDiscoveryInvestorSeries #ArtificialIntelligenceinDrugDiscoveryMarket #AIindrugdiscoveryinvestmentopportunity #Artificalintelligenceindrugdiscoveryinvestors
Rise in clinical research activity for genetically modified therapies has resulted in the increase in demand for vectors, offering lucrative opportunities to players having capabilities for in-house and contract manufacturing of various types of vectors
Roots Analysis has announced the addition of “Viral Vector, Non-Viral Vector and Gene Therapy Manufacturing Market (5th Edition), 2022-2035” report to its list of offerings.
The report features an extensive study on the extensive study of the current landscape and the likely future potential of viral vector, non-viral vector and gene therapy manufacturing market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:
An overview of the current status of the market with respect to the players engaged in the manufacturing of viral, non-viral and other novel types of vectors and gene therapies. It features information on the year of establishment, company size, location of headquarters, type of product manufactured, location of manufacturing facilities, type of manufacturers, scale of operation, type of vector manufactured and application area
An analysis of the technologies offered / developed by the companies engaged in this domain, based on the type of technology, type of manufacturer, scale of operation, type of vector involved, application area. It also highlights the most prominent players within this domain, in terms of number of technologies.
A region-wise, company competitiveness analysis, highlighting key players engaged in the manufacturing of vectors and gene therapies, across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration supplier strength (based on experience in this field), manufacturing strength, service strength.
Elaborate profiles of key players based in North America, Europe and Asia-Pacific (shortlisted based on proprietary criterion). Each profile features an overview of the company / organization, its financial performance (if available), information related to its manufacturing facilities, vector manufacturing technology and an informed future outlook.
Tabulated profiles of the other key players headquartered in different regions across the globe (shortlisted based on proprietary criterion). Each profile features an overview of the company, its financial performance (if available), information related to its manufacturing capabilities, and an informed future outlook.
An analysis of partnerships and collaborations established in this domain since 2015; it includes details of deals that were / are focused on the manufacturing of vectors, which were analyzed on the basis of year of partnership, type of partnership, scale of operation, type of vector involved, region and most active players.
An analysis of the expansions related to viral vector and non-viral vector manufacturing, which have been undertaken since 2015, based on several parameters, such as year of expansion, type of expansion, type of vector and geographical location of the expansion.
An analysis evaluating the potential strategic partners for vector and gene therapy product manufacturers, based on several parameters, such as developer strength, product strength, type of vector, therapeutic area, pipeline strength.
An overview of other viral / non-viral gene delivery approaches that are currently being researched for the development of therapies involving genetic modification.
An in-depth analysis of viral vector and plasmid DNA manufacturers, featuring three schematic representations, a three dimensional grid analysis, representing the distribution of vector manufacturers (on the basis of type of vector) across various scales of operation and type of manufacturer, a heat map of viral vector and plasmid DNA manufacturers based on the type of vector and type of organization, and a schematic world map representation, highlighting the headquarters and geographical location of key vector manufacturing hubs.
An analysis of the various factors that are likely to influence the pricing of vectors, featuring different models / approaches that may be adopted by product developers / manufacturers in order to decide the prices of proprietary vectors.
An estimate of the overall, installed vector manufacturing capacity of industry players based on the information available in the public domain, and insights generated via both secondary and primary research. The analysis also highlights the distribution of the global capacity by company size, scale of operation, type of vector and region.
An informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency and dose strength.
A discussion on the factors driving the market and various challenges associated with the vector production process.
A qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of drug developers, bargaining power of vector and gene therapy manufacturers, threats of substitute technologies and rivalry among existing competitors.
By 2035, the financial opportunity within the viral vector manufacturing, non-viral vector manufacturing and gene therapy manufacturing market has been analyzed across the following segments:
Scale of Operation
Lab
Clinical
Commercial
Type of Vectors
AAV
Adenoviral
Lentiviral
Retroviral
Plasmid DNA
Other Vectors
Application Area
Gene Therapy
Cell Therapy
Vaccines
Therapeutic Area
Oncological Disorders
Rare Disorders
Neurological Disorders
Sensory Disorders
Metabolic Disorders
Musco-skeletal Disorders
Blood Disorders
Immunological Diseases
Others
Geographical Regions
North America
Europe
Asia Pacific
Latin America
MENA
Rest of the World
Key Companies covered in the report
Advanced BioScience Laboratories
Aldevron
Audentes Therapeutics
BioNTech Innovative Manufacturing
BioReliance
Biovian
bluebird bio
Cell and Gene Therapy Catapult
Celonic
Centre for Process Innovation
Cobra Biologics
Emergent BioSolutions
FinVector
FUJIFILM Diosynth Biotechnologies
Kaneka Eurogentec
Lonza
MeiraGTx
MolMed
Novasep
Orchard Therapeutics
Oxford BioMedica
Richter-Helm
Sanofi
Spark Therapeutics
Thermo Fisher Scientific
uniQure
Vibalogics
Vigene Biosciences
VIVEbiotech
Wuxi AppTech
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html
You may also be interested in the following titles:
Lab Automation Market
Cannabis Testing Market
You may also like to learn what our experts are sharing in Roots educational series:
Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders
4D Bioprinting Market: Key Trends
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com
#ViralVectorManufacturingMarket #GenetherapyManufacturing #VectorManufacturing #Vectormanufacturingmarket #NonViralvectorManufacturingMarket
The latest report entitled ‘Non-Viral Drug Delivery Systems Market’ by Roots Analysis provides an accurate estimation of the market size, regional landscape description, and revenue forecast over the projected timeframe.
The report turns the spotlight on the major challenges faced by the key players in the global market and the growth strategies currently adopted by them. The report is a granular assessment of this particular business sphere and entirely covers the dynamic competitive landscape of the market. The document offers key insights into the market positions of these players alongside their gross earnings. Furthermore, it elaborates on each of the market segments, with detailed scrutiny of the development scope and competitive scenario of the regional fragments of the market.
The latest study is inclusive of an in-depth analysis of the economic status of the Non-Viral Drug Delivery Systems market and examines the most important regions constituting the global market. It further details on the most lucrative and growth-oriented regions, top market rivals, diversified product types, and a large number of end-use industries.
Key factors affecting the growth of the Non-Viral Drug Delivery Systems market:
Geographical Overview:
• The latest report broadly categorizes the Non-Viral Drug Delivery Systems market into several geographical terrains, including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
• The study is inclusive of essential information relevant to each region in this broad industry segment, along with the key drivers of the regional market growth.
• The report further estimates the revenue accumulated by these regions over the forecast period.
Competitive Hierarchy:
• The latest research report studies the major market players, their regional presence, industry share, and production facilities.
• The report offers significant data pertaining to these market competitors’ company profiles, product types, and application outlook.
• Moreover, the pricing models and gross margins of these industry majors have also been mentioned in the report.
Additional parameters of the Intracellular Drug Delivery Systems market report:
• The latest research study endows the reader with a comprehensive analysis of the product types of the Non-Viral Drug Delivery Systems market, categorizing the relevant information into the market share, production growth rate, and profit valuation of each product type. The study focuses on the wide-ranging application landscape of the market, segmenting it into the market share, estimated growth rate, and the forecast product demand for each application type.
Additional Insights:
• The market concentration rate and processing rate of raw materials have also been conscripted in the report.
• The report contains an assessment of the current price trends, as well as the factors influencing the global market size.
• It throws light on the significant marketing strategies implemented by the eminent players in the industry.
• Vital data and information concerning the producers, distributors, and downstream buyers involved in the global market, as well as the cost structure analysis and market mechanism, form the important elements of this report.
Research objectives:
• The Non-Viral Drug Delivery Systems market report studies the worldwide market consumption rate in terms of value and volume.
• It identifies the various sub-segments of the market structure.
• It proffers information regarding the leading global manufacturers in this industry, describing their market value & share, sales volume, competitive analysis, SWOT analysis, and development strategies adopted during the forecast timeline.
• The report describes the key industry players, with respect to their individual growth trends, future prospects, and contribution to the global market, and explains the factors related to their market growth potential, drivers, opportunities, threats, and industry-specific challenges.
• Furthermore, the report underpins the strategic developments occurring in the Non-Viral Drug Delivery Systems market, such as expansions, mergers & acquisitions, agreements, as well as new product launches.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/non-viral-drug-delivery-systems-market.html
You may also be interested in the following titles:
Pharmaceutical Polymers / Medical Polymers Market
Gene Switch Market
You may also like to learn what our experts are sharing in Roots educational series:
Advancements in Automation of Processes: Key Value Driver for Escalated Interest in Cell Therapies Manufacturing Domain
CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#nonviraldrugdeliverysystemmarket #nonviraldrugdeliverysystemmarketSize #genedeliverysystems #intracellulardelivery #intracellular #drugdelivery
The latest research report titled ‘MRNA Synthesis and Manufacturing Services Market’, published by Roots Analysis systematically explains every single component of the MRNA Synthesis and Manufacturing Services Market, assisting the readers with an in-depth analysis of this industry vertical.
Besides, the report offers a brief overview of the different market segments and explicates the current market scenario with the help of a precise summary of the global market. The MRNA Synthesis and Manufacturing Services Market can be characterized by its current position, industry size, anticipated revenue, and the potential market share and volume over the forecast timeframe. Alongside the above-mentioned information, the report offers meaningful insights into the regional outlook of the global market. An all-inclusive study of the competitive backdrop of the MRNA Synthesis and Manufacturing Services Market is a significant element of the latest report.
Major Highlights of the ToC:
Market Dynamics:
• Market Trends
• Opportunities
• Market Drivers
• Challenges
• Influence Factors
Developmental Trend Analysis:
• Market Trend Analysis
• Market Size (Volume and Value)
Methodology/Research Approach:
• Research Programs/Design
• Market Size Estimation
• Market Breakdown and Data Triangulation
• Data Source
Regional Bifurcation:
• The latest report categorizes the MRNA Synthesis and Manufacturing Services Market into various regions across the globe, based on their market dominance and revenue share.
• The report briefs about the market share data of each of the regional segments, along with the potential growth drivers of these regions.
• The report includes valuable insights into the import and export trends, revenue estimation, and production and consumption rates, as well as the leading players of each region.
Prominent factors influencing the competitive landscape of the global market:
• The report offers an extensive analysis of the competitive landscape of the MRNA Synthesis and Manufacturing Services Market, profiling the most prominent market players.
• The report includes data pertaining to the manufacturing facilities of the key industry players, along with the market shares they hold and the regions they operate in.
• Furthermore, the document covers the product catalog of leading companies, product specifications and common application types, pricing models, and the gross margins set by these companies.
Other significant aspects determining the global market remuneration over the projected timeline:
• The MRNA Synthesis and mRNA Manufacturing Services Market report elaborates on the diverse product range, as well as the scope of product application of this particular business vertical.
• The report also encompasses other vital information associated with the global market, for instance, market share, production growth rate, net profit, and application segments.
• The key factors like market concentration rate, raw material processing rate, current price trends, and estimated growth prospects of the industry have also been evaluated in this report.
• The report draws a precise inference of the MRNA Synthesis and Manufacturing Services Market, giving details about the marketing approach of the leading companies, their market positions, and marketing channel development.
• Additionally, the report encapsulates information related to the producers, distributors, and downstream buyers involved in this industry, and briefs about the manufacturing cost structure.
Get more details on the MRNA Synthesis and Manufacturing Services Market report
https://www.rootsanalysis.com/reports/mrna-synthesis-and-manufacturing-market.html
You may also be interested in the following titles:
Decentralized Clinical Trials / Virtual Clinical Trials Market
Global Antibiotics Market
You may also like to learn what our experts are sharing in Roots educational series:
Introduction To Exosome Therapeutics
Unlocking the Potential of Digital Twins in Healthcare: Benefits, Challenges and Opportunities
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#mRNASynthesisandManufacturingServicesMarketTrends #mRNASynthesisandManufacturingServicesMarketGrowth #mRNAcontractmanufacturing
Roots Analysis has done a detailed study on TIL-based Therapies, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
Over 75 TIL-based therapies are being evaluated across different stages of preclinical / clinical development either as monotherapies or in combination with other drugs for the treatment of various oncological disorders
Both industry and non-industry players have demonstrated keen interest in the development of novel TIL-based therapies; further, melanoma emerged as the most popular target indication
Majority (56%) of industry players based in North America are actively undertaking efforts for the development / commercialization of TIL-based cell therapies; the industry is dominated by the presence of mid-sized players
Over the past decade, close to 95 clinical trials have been registered across different geographies for the evaluation of TIL-based therapies; extensive efforts are underway to improve the successive generations of such therapies
Close to 55 scientists from renowned universities are presently involved in the clinical development of TIL-based therapies; majority of these KOLs are primarily based in the US and China
Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development
A growing interest in development of TIL-based therapies is reflected from the increase in R&D agreements in the last few years; majority of the such deals were signed between players based in North America
Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 2.7 billion, across 30 instances, since 2013
With a More than 165 patents have been filed / granted by various stakeholders in order to protect the intellectual property generated within this field
With a growing focus on the development pipeline and encouraging clinical results, the TIL therapies market is anticipated to witness an annualized growth rate of 40%, in the next decade
Table of Contents
-
PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
-
EXECUTIVE SUMMARY -
INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.7. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
3.7.2. Development of TILs Therapy
3.8. Key Benefits and Roadblocks
3.9. Concluding Remarks
-
TIL-BASED THERAPIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. TIL-based Therapies: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Key Target Indications
4.2.5. Analysis by Source of T-Cells
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Dosing Frequency
4.2.8. Analysis by Target Patient Segment
4.2.9. Analysis by Type of Therapy
4.2.10. Most Active Industry Players: Analysis by Number of TIL-based Therapies
4.2.11. Most Active Non-Industry Players: Analysis by Number of TIL-based Therapies
4.3. TIL-based Therapies: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
-
CLINICAL TRIAL ANALYSIS
5.1. Chapter Overview
5.2. Scope and Methodology
5.3. TIL-based Therapies: Clinical Trial Analysis
5.3.1. Analysis by Trial Registration Year
5.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
5.3.3. Analysis by Trial Status
5.3.4. Analysis by Trial Registration Year and Trial Status
5.3.5. Analysis by Trial Phase
5.3.6. Analysis by Trial Phase and Enrolled Patient Population
5.3.7. Analysis by Target Patient Segment
5.3.8. Analysis by Type of Sponsor / Collaborator
5.3.9. Analysis by Study Design
5.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
5.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
5.3.12. Word Cloud Analysis: Emerging Focus Areas
5.3.13. Analysis of Clinical Trials by Geography
5.3.14. Analysis of Enrolled Patient Population by Geography
-
KEY OPINION LEADERS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. TIL-based Therapies: Key Opinion Leaders
6.4.1. Analysis by Type of Organization
6.4.2. Analysis by Affiliated Organization
6.4.3. Analysis by Qualification
6.4.4. Analysis by Geographical Location of KOLs
6.4.5. KOL Activeness versus KOL Strength
6.4.6. Most Prominent KOLs: Analysis by RA score
6.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
-
TIL-BASED THERAPY PROFILES
7.2. LN-144 / Lifileucel (Iovance Biotherapeutics)
7.3. LN-145 (Iovance Biotherapeutics)
7.4. ITIL-168 (Instil Bio)
7.5. LTX-315 (Lytix Biopharma)
-
PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. TIL-based Therapies: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partnership
8.3.4. Analysis by Type of Partner
8.3.5. Most Popular Products: Analysis by Number of Partnerships
8.3.6. Most Active Industry Players: Analysis by Number of Partnerships
8.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
8.3.8. Analysis by Geography
-
FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Type of Funding
9.3. TIL-based Therapies: Funding and Investment Analysis
9.3.1. Analysis by Year of Investment
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Type of Investor
9.3.5. Most Active Players: Analysis by Number of Instances
9.3.6. Most Active Investors: Analysis by Amount Invested
9.3.7. Analysis of Amount Invested by Geography
9.3.8. Most Active Investors: Analysis by Number of Funding Instances
-
PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. TIL-based Therapies: Patent Analysis
10.3.1. Analysis by Patent Publication Year
10.3.2. Analysis By Patent Application Year
10.3.3. Analysis by Geography
10.3.4. Analysis by Type of Player
10.3.5. Analysis by CPC Symbols
10.3.6. Word Cloud Analysis: Emerging Focus Areas
10.3.7. Leading Players: Analysis by Number of Patents
10.3.8. TIL-based Therapies: Patent Benchmarking
10.3.9. Analysis By Patent Characteristics
10.3.10. TIL-based Therapies: Patent Valuation
-
CASE STUDY: CELL THERAPY MANUFACTURING
11.1. Chapter Overview
11.2. Overview of Cell Therapy Manufacturing
11.3. Cell Therapy Manufacturing Models
11.3.1. Centralized Manufacturing Model
11.3.2. Decentralized Manufacturing Model
11.4. Scalability of Cell Therapy Manufacturing Processes
11.4.1. Scale-Up
11.4.2. Scale-Out
11.5. Types of Cell Therapy Manufacturers
11.6. Key Challenges Related to Manufacturing of Cell Therapies
11.7. Important Factors for Cell Therapy Manufacturing
11.7.1. Characterization
11.7.2. Cost of Goods
11.8. Automation of Cell Therapy Manufacturing Process
11.9. Cell Therapy Manufacturing Supply Chain
11.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
11.11. Regulatory Landscape
11.12. Future Perspectives
-
COST PRICE ANALYSIS
12.1. Chapter Overview
12.2. Factors Contributing to the High Price of Cell / Gene Therapies
12.3. Pricing Models for T-Cell Immunotherapies
12.3.1. Based on Associated Costs
12.3.2. Based on Availability of Competing Products
12.3.3. Based on Patient Segment
12.3.4. Based on Opinions of Industry Experts
12.4. Reimbursement related Considerations for T-Cell Immunotherapies
-
MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
3.4. Global TIL-Based Therapies Market, 2022-2035
13.4.1. TIL-based Therapies Market: Analysis by Target Indication
13.4.2. TIL-based Therapies Market: Analysis by Key Players
13.4.3. TIL-based Therapies Market: Analysis by Key Geographical Regions
13.4.4. Product Wise Sales Forecast
13.4.4.1. Lifileucel / LN-144 (Iovance Biotherapeutics)
13.4.4.2. LN-145 (Iovance Biotherapeutics)
13.4.4.3. LTX-315 and TILs (Lytix Biopharma)
13.4.4.4. TILs (Prometheus Laboratories)
13.4.4.5. Donor Lymphocyte Infusion (Incyte)
13.4.4.6. ITIL-168 (Instil Bio)
13.4.4.7. IOV-2001 (Iovance Biotherapeutics)
13.4.4.8. TILs (CAR-T (Shanghai) Cell Biotechnology)
13.4.4.9. TILs (Bristol-Myers Squibb)
-
COMPANY PROFILES
14.1. Chapter Overview
14.2. Cellectis
14.3. Cellular Biomedicine Group
14.4. Iovance Biotherapeutics
14.5. Lytix Biopharma
14.6. Phio Pharmaceuticals
-
CONCLUDING REMARKS -
EXECUTIVE INSIGHTS -
APPENDIX I: TABULATED DATA -
APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/til-therapies-market.html
You may also be interested in the following titles:
Pharmaceutical Polymers / Medical Polymers Market
Gene Switch Market
You may also like to learn what our experts are sharing in Roots educational series:
At-home Self-testing: A Giant Leap Towards Transformation in Diagnostic Sector
SARM1: A Potential Therapeutic Target For Neurodegenerative Diseases
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#TILTherapiesMarketSize #TILTherapiesMarketGrowth #TILimmunotherapies #TILbasedproducts #TILMarket
In the last few years, many contract research organizations (CROs) have emerged and significantly impacted the overall biopharmaceutical market.
It is worth mentioning that the presence of CROs has enabled small and mid-sized companies, which lack the necessary expertise and elaborate resources, to successfully initiate R&D programs in several domains.
The financial opportunity within the Cell and Gene Therapy CROs Market has been analyzed across the following segments:
Area of Expertise
Cell Therapy
Gene Therapy
Scale of Operation
Preclinical
Clinical
Drug Discovery
Therapeutic Area
Oncological Disorders
Neurological Disorders
Cardiovascular Disorders
Infectious Diseases
Metabolic Disorders
Autoimmune Disorders
Blood Disorders
Rare / Genetic Disorders
Ophthalmic Disorders
Other disorders
Analysis by Geographical Regions
North America
Europe
Asia Pacific
Latin America
Middle East and North Africa
The Cell and Gene Therapy CROs Market, 2022-2035 report features the following companies, which we identified to be key players in this domain:
Altasciences
Charles River Laboratories
Creative Biolabs
IQVIA
Medpace
PPD
Precision for Medicine
Accelera
Evotec
ICON
Syneos Health
CMIC Group
Labcorp
Table of Contents
-
Preface
-
Executive Summary
-
Introduction
-
Guide To Outsourcing
-
Market Landscape
-
Company Profiles
-
Competitive Benchmarking
-
Partnerships And Collaborations
-
Mergers and Acquisitions -
Key Acquisition Targets -
Likely Partner Analysis for Cell Therapy CROs -
Likely Partner Analysis for Gene Therapy CROs -
Clinical Trial Analysis -
Total Cost of Ownership for Cell and Gene Therapy Contract Research Organizations -
Market Forecast and Opportunity Analysis -
Swot Analysis -
Conclusion -
Interview And Survey Transcripts -
Appendix 1: Tabulated Data -
Appendix 2: List of Companies and Organizations
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/cell-and-gene-therapy-cros-market/230.html
You may also be interested in the following titles:
Women’s Digital Health Market
Modular Manufacturing Facilities Market
You may also like to learn what our experts are sharing in Roots educational series:
Is Blue Ocean Strategy The Silver Bullet For Emerging Teleradiology Players to Achieve A Breakthrough In This Highly Competitive Market?
Artificial Intelligence (AI) In Oncology: Current Scenario And Future Potential
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#CellandgenetherapyCROMarket #CellandgenetherapyCROMarketGrowth #Geneandcelltherapy #cellandgenetherapycro #cellandgenetherapies
Roots Analysis has announced the addition of “Bacteriophage Therapeutics Market, 2022-2035” report to its list of offerings.
Key Market Insights
Over 100 bacteriophage therapeutics have either been marketed / are being developed by various well-established and small firms; majority of these therapeutics are being evaluated for the treatment of infectious diseases
Around 50% of the pipeline candidates are currently under clinical phase of development; of these, close to 50% are designed for oral and topical administration
Multiple clinical studies, evaluating various types of bacteriophage therapeutics among more than 3,000 patients across different centers / hospitals, have been registered worldwide
Over the years, the intellectual capital related to bacteriophage therapeutics has grown at a significant pace, with several patents being filed by both industry and non-industry players
A notable increase in published scientific literature related to bacterio-phage therapeutics has been observed over the years, demonstrating the growing interest in this domain
Various organizations have extended financial support to aid the ongoing research for bacteriophage therapies; currently, the focus, in terms of funds disbursed, is on clinical investigation of bacteriophage therapeutics
Several investors, having realized the benefits and future opportunity, have invested over USD 1 billion since 2017
The rising interest of stakeholders is also reflected by the number of partnerships signed in the recent past, involving players located in different geographical regions
Our proprietary start-up health indexing analysis confirms the presence of several new entrants that claim to possess the required capabilities for developing bacteriophage therapeutics
The market is anticipated to grow at a CAGR of ~10% till 2035; the forecasted opportunity is likely to be distributed across different therapeutic areas, routes of administration, and geographical regions
Table of Content
-
PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
-
EXECUTIVE SUMMARY -
INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Bacteriophages
3.3. Biology of Bacteriophages
3.4. Introduction to Bacteriophage Therapy
3.5. Applications of Bacteriophage Therapy
3.6. Advantages of Bacteriophage Therapy
3.7. Limitations of Bacteriophage Therapy
3.8. Conclusion
-
BACTERIOPHAGE THERAPEUTICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Bacteriophage Therapeutics: Drug Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Therapeutic Area
4.2.3. Analysis by Phase of Development and Therapeutic Area
4.2.4. Analysis by Targeted Bacterial Strain
4.2.5. Analysis by Target Disease Indication
4.2.6. Analysis by Type of Therapy
4.2.7. Analysis by Route of Administration
4.3. Information on Bacteriophage Related Technologies
-
BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE
5.1. Chapter Overview
5.2. Bacteriophage Therapeutics: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Leading Developers: Analysis by Number of Bacteriophage Therapeutics
-
COMPANY AND DRUG PROFILES
6.1. Chapter Overview
6.2. Eliava BioPreparations
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Pipeline Overview
6.2.3.1. Pyo Bacteriophage
6.2.3.2. Intesti Bacteriophage
6.2.3.3. SES Bacteriophage
6.2.3.4. Staphylococcal Bacteriophage
6.2.3.5. Fersisi Bacteriophage
6.2.3.6. Enko Bacteriophage
6.2.4. Recent Developments and Future Outlook
6.3. Micreos
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Pipeline Overview
6.3.3.1. PhageGuard Listex
6.3.3.2. PhageGuard S
6.3.3.3. PhageGuard E
6.3.4. Recent Developments and Future Outlook
6.4. NPO Microgen
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Pipeline Overview
6.4.3.1. E. coli-Proteus Bacteriophage
6.4.3.2. Streptococcus Bacteriophage
6.4.3.3. Complex Pyobacteriophage
6.4.3.4. Klebsiella Purified Polyvalent Bacteriophage
6.4.3.5. Sextaphag
6.4.3.6. Dysentery Bacteriophage
6.4.3.7. Intesti
6.4.4. Recent Developments and Future Outlook
6.5. ContraFect
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Pipeline Overview
6.5.3.1. Exebacase (CF-301)
6.5.3.2. CF-296
6.5.3.3. CF-370
6.5.3.4. Gram-Negative Lysins
6.5.3.5. Amurins
6.5.4. Recent Developments and Future Outlook
6.6. Adaptive Phage Therapeutics
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Pipeline Overview
6.6.3.1. Bacteriophage Therapeutics
6.6.4. Recent Developments and Future Outlook
6.7. Phagelux
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Pipeline Overview
6.7.3.1. PGX-0100
6.7.3.2. BactelideTM
6.7.3.3. BactelideTM
6.7.4. Recent Developments and Future Outlook
6.8. Pherecydes Pharma
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Pipeline Overview
6.8.3.1. Bacteriophage Therapeutics
6.8.4. Recent Developments and Future Outlook
-
CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Bacteriophage Therapeutics Market: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
7.3.3. Analysis by Trial Status
7.3.4. Analysis by Trial Phase and Enrolled Patient Population
7.3.5. Analysis by Study Design
7.3.6. Analysis by Type of Sponsor / Collaborator
7.3.7. Most Active Players: Analysis by Number of Registered Trials
7.3.8. Regional Analysis
7.3.8.1. Analysis by Number of Registered Trials
7.3.8.2. Analysis by Enrolled Patient Population
-
PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Bacteriophage Therapeutics: Patent Analysis
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Patent Application Year
8.3.3. Analysis by Annual Number of Granted Patent(s) and Patent Application(s)
8.3.4. Analysis by Geography
8.3.5. Analysis by CPC Symbols
8.3.6. Analysis by Type of Applicant
8.3.7. Leading Players: Analysis by Number of Patents
8.4. Bacteriophage Therapeutics: Patent Benchmarking
8.4.1. Analysis by Patent Characteristics
8.5. Bacteriophage Therapeutics: Patent Valuation
8.6. List of Leading Patents
-
PUBLICATION BENCHMARKING ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.2.1. Analysis by Year of Publication
9.2.2. Analysis by Type of Article
9.2.3. Analysis by Popular Keywords
9.2.4. Popular Publishers: Analysis by Number of Publications
9.2.5. Popular Journals: Analysis by Number of Publications
9.2.6. Popular Journals: Analysis by Journal Impact Factor
9.2.7. Publications: Timeline Analysi
9.3. Publication Benchmarking
-
ACADEMIC GRANTS ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Bacteriophage Therapeutics: Academic Grant Analysis
10.3.1. Analysis by Year of Grant Award
10.3.2. Analysis by Amount Awarded
10.3.3. Analysis by Administering Institute Center
10.3.4. Analysis by Support Period
10.3.5. Analysis by Funding Institute Center and Support Period
10.3.6. Analysis by Type of Grant Application
10.3.7. Analysis by Purpose of Grant Award
10.3.8. Analysis by Activity Code
10.3.9. Word Cloud Analysis: Emerging Focus Areas
10.3.10. Analysis by Study Section Involved
10.3.11. Popular NIH Departments: Analysis by Number of Grants
10.3.12. Analysis by Type of Recipient Organization
10.3.13. Prominent Program Officers: Analysis by Number of Grants
10.3.14. Popular Recipient Organizations: Analysis by Number of Grants
10.3.15. Regional Distribution of Recipient Organizations
-
FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Bacteriophage Therapeutics Market: List of Funding and Investments
11.3.1. Analysis by Year of Investment
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Most Active Players: Analysis by Number of Funding Rounds and Amount Raised
11.3.5. Investors Analysis
11.3.6. Regional Distribution by Amount Invested
11.4. Concluding Remarks
-
PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Bacteriophage Therapeutics: List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year of Partnership and Type of Partner
12.3.4. Analysis by Therapeutic Area
12.3.5. Analysis by Application Area
12.3.6. Most Active Players: Analysis by Number of Partnerships
12.3.7. Regional Analysis
12.3.7.1. Intercontinental and Intracontinental Agreements
-
START-UP HEALTH INDEXING
13.1. Chapter Overview
13.2. Bacteriophage Therapeutics Developers: Start-ups
13.2.1. Analysis by Location of Headquarters
13.3. Benchmarking of Start-ups
13.3.1. Analysis by Pipeline Strength
13.3.2. Analysis by Pipeline Maturity
13.3.3. Analysis by Indication Diversity
13.3.4. Analysis by Number of Patents
13.3.5. Analysis by Funding Amount
13.3.6. Analysis by Partnership Activity
13.3.7. Start-ups Health Indexing: Roots Analysis Perspective
-
MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Assumptions
14.3. Forecast Methodology
14.4. Global Bacteriophage Therapeutics Market, 2022-2035
14.4. 1. Bacteriophage Therapeutics Market, 2022-2035: Distribution by Therapeutic Area
14.4.1.1. Bacteriophage Therapeutics Market for Gastrointestinal Infectious, 2022-2035
14.4.1.2. Bacteriophage Therapeutics Market for Bacterial Dysentery, 2022-2035
14.4.1.3. Bacteriophage Therapeutics Market for Multiple Infections, 2022-2035
14.4. 2. Bacteriophage Therapeutics Market, 2022-2035: Distribution by Route of Administration
14.5.2.1. Bacteriophage Therapeutics Market for Oral Therapies, 2022-2035
14.5.2.2. Bacteriophage Therapeutics Market for Rectal Therapies, 2022-2035
14.5.2.3. Bacteriophage Therapeutics Market for Intravesical Therapies, 2022-2035
14.5.2.4. Bacteriophage Therapeutics Market for Topical Therapies, 2022-2035
14.4. 3. Bacteriophage Therapeutics Market, 2022-2035: Distribution by Geography
14.6.3.1. Bacteriophage Therapeutics in North America, 2022-2035
14.6.3.2. Bacteriophage Therapeutics in Europe, 2022-2035
-
CONCLUSION -
EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Rime Bioinformatics
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Antoine Culot, Chief Executive Officer
16.3. BiomX
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Iddo Weiner, Senior Director, Head of Data-Science
16.4. Hospices Civils De Lyon
16.4.1. Organization Snapshot
16.4.2. Interview Transcript: Mathieu Medina, Project Leader
16.5. Independent Consultant
16.5.1. Interview Transcript: Mohammadreza Azizkhani, Scientific Researcher
-
APPENDIX I: TABULATED DATA -
APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html
You may also be interested in the following titles:
Lab Automation Market
Cannabis Testing Market
You may also like to learn what our experts are sharing in Roots educational series:
T-cell Immunotherapies: The Future of Modern Cancer Treatments
Monkeypox: Disease Overview, Transmission and Diagnosis
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#Bacteriophagetherapeuticsmarket #Bacteriophagetherapeuticsmarketsize #bacteriophage #phage# bacteriophagetherapy
The traditional statistical tools and techniques available for medical data interpretation are known to be associated with challenges related to time and cost.
This has prompted industry stakeholders to explore the applications of deep learning-based technologies, specifically across drug discovery and diagnosis. In addition, recent investments made in this domain are likely to offer lucrative opportunities to companies offering deep learning-based technologies / solutions within the healthcare industry.
The financial opportunity associated with cell therapy manufacturing market has been analyzed across the following segments:
Therapeutic Area
Oncological Disorders
Infectious Diseases
Neurological Disorders
Immunological Disorders
Endocrine Disorders
Cardiovascular Disorders
Respiratory Disorders
Ophthalmic Disorders
Musculoskeletal Disorders
Inflammatory Disorders
Other Disorders
Key Geographical Regions
North America
Europe
Asia Pacific
Rest of the World
The Deep Learning in Drug Discovery and Deep Learning in Diagnostics Market (2nd Edition), 2023-2035 report features the following companies, which we identified to be key players in this domain:
Aegicare
Aiforia Technologies
Ardigen
Berg
Google
Huawei
Merative
Nference
NVIDIA
Owkin
Phenomic AI
Pixel AI
Table of Contents
-
PREFACE
-
EXECUTIVE SUMMARY
-
INTRODUCTION
-
MARKET OVERVIEW: DEEP LEARNING IN DRUG DISCOVERY
-
MARKET OVERVIEW: DEEP LEARNING IN DIAGNOSTICS
-
COMPANY PROFILES
-
PORTER’S FIVE FORCES ANALYSIS
-
CLINICAL TRIAL ANALYSIS
-
FUNDING AND INVESTMENT ANALYSIS
-
START-UP HEALTH INDEXING
-
COMPANY VALUATION ANALYSIS
-
MARKET SIZING AND OPPORTUNITY ANALYSIS: DEEP LEARNING IN DRUG DISCOVERY
-
MARKET SIZING AND OPPORTUNITY ANALYSIS: DEEP LEARNING IN DIAGNOSTICS
-
DEEP LEARNING IN HEALTHCARE: EXPERT INSIGHTS
-
CONCLUDING REMARKS
-
INTERVIEW TRANSCRIPTS
-
APPENDIX 1: TABULATED DATA
-
APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/view_document/deep-learning-in-drug-discovery-market/156.html
You may also be interested in the following titles:
Gene Switch Market
Digital Biomanufacturing Market
You may also like to learn what our experts are sharing in Roots educational series:
Unlocking the Potential of Digital Twins in Healthcare: Benefits, Challenges and Opportunities
Investment Opportunities in Women’s Digital Health
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#DeepLearninginDrugDiscoveryMarketTrends #DeepLearninginDrugDiscoveryMarketGrowth #machinelearningtechniques #deeplearningalgorithms #deeplearningtechnologies
The “Non-Viral Drug Delivery Systems Market report features an extensive study of the current landscape and the likely future opportunities of players engaged in offering intracellular drug delivery technologies in the healthcare domain, over next 12 years.
Key Inclusions
An executive summary of the key insights captured during our research, offering a high-level view on the current state of the non-viral drug delivery systems market and its likely evolution in the short to mid and long term.
A brief introduction to important concepts related to non-viral intracellular drug delivery, featuring information on various types of non-viral drug delivery systems and their primary applications in the healthcare domain, along with details related to the recent advancements that have been reported in this market space.
A detailed review of the overall market landscape of non-viral drug delivery systems, featuring an in-depth analysis based on several relevant parameters, such as therapeutic portfolio, type of molecule delivered (small molecules and biologics), type of biologic delivered (antibodies, DNA, RNA and proteins / peptides), type of interaction (co-administration, conjugation, encapsulation and others) and Type of Technology (cell penetrating peptides, extracellular vesicles, oligonucleotides, nanoparticles, polymers). In addition, it features a list of technology developers and a detailed analysis based on their year of establishment, company size, type of company and geographical location.
An in-depth analysis, highlighting the contemporary market trends, using four schematic representations, including a waffle chart representation, (highlighting the distribution of various types of vehicles used for delivering payloads), a heat map representation (based on company size and type of molecule delivered), a vertical stacked column bar chart representation (location of headquarters and type of service provider), a vertical column clustered chart representation (based on company size and location of headquarters).
An insightful company competitiveness analysis of non-viral drug delivery systems providers, taking into consideration various relevant parameters, such as years of experience and product portfolio (in terms of number of technologies offered, type of biologics delivered and type of linkage) and partnership strength (in terms of number of partnerships, partnership year, partnerships based on geographies, type of partnerships, therapeutic area, payment portfolio and type of biologics delivered).
Elaborate profiles of prominent players engaged in offering non-viral drug delivery technologies, across North America, Europe and Asia. Each company profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and key members of the executive team), details on its technology portfolio and recent developments and an informed future outlook.
An in-depth analysis of the various patents that have been filed / granted patent related to intracellular drug delivery technologies, based on various parameters, such as type of patent, publication year, application year, granted patents, filed patents, issuing authority, type of player, CPC symbols (in terms of the size of intellectual property portfolio), leading industry / non-industry players and inventors (in terms of number of patents filed / granted). Further it features a patent benchmarking analysis and a detailed patent valuation analysis.
An insightful analysis of various partnerships inked between stakeholders engaged within the non-viral drug delivery domain, based on several relevant parameters, such as year of partnership, type of partner (industry and non-industry), purpose of partnership (research and development, research, development and commercialization, product development, product development and commercialization, product development and manufacturing, product development and manufacturing, commercialization, manufacturing, acquisition / merger and others), type of partnership (technology licensing agreements, technology evaluation agreements, technology integration agreements, technology utilization agreements, acquisitions / mergers and others), therapeutic area (oncological disorders, infectious diseases, genetic disorders, hepatic disorders, neurological disorders, cardiovascular disorders, ophthalmic diseases, pulmonary diseases, metabolic disorders, immunological disorders and others), type of payment model (upfront payments, milestone payments, royalties and others), type of molecule delivered (small molecules, biologics), type of biologic delivered (antibodies, RNA, DNA and proteins / peptides), most active players (in terms of number of deals inked), most popular technologies (in terms of number of deals inked for technologies) and regional distribution of partnership activity that have been undertaken in this domain, during the period 2015-2022.
An insightful framework which provides four zones of evaluation and product portfolio matrix based on various parameters, such as number of drugs in the pipeline, number of companies, deal amount, partnership activity, trends highlighted in number of grants, number of publications, google hits and qualitative scoring. It also provides a Kalbach, competitive assessment framework and BCG matrix for respective non-viral drug delivery technologies currently employed by stakeholders.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Type of Molecule
Small Molecule
Biologic
Type of Biologic
Antibodies
DNA
RNA
Proteins / Peptides
Type of Technologies
Cell Penetrating Peptides
Extracellular Vesicles
Oligonucleotides
Nanoparticles
Polymers
Target Therapeutic Area
Infectious Diseases
Oncological Disorders
Genetic Disorders
Neurological Disorders
Hepatic Disorders
Cardiovascular Disorders
Other Disorders
Type Of Payment Model
Upfront Payments
Milestone Payments
Key Geographical Regions
North America
Europe
Asia
Latin America
Middle East and North Africa (MENA)
Rest of the world
Key Questions Answered
Who are the leading players engaged in the development of intracellular drug delivery technologies?
Which partnership models are commonly adopted by stakeholders engaged in this domain?
What type of molecules can be delivered using intracellular drug delivery technologies?
How is the intellectual property landscape related to intracellular drug delivery likely to evolve in the foreseen future?
How is the current and future market opportunity likely to be distributed across key market segments and geographical regions?
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/non-viral-drug-delivery-systems-market.html
You may also be interested in the following titles:
Decentralized Clinical Trials / Virtual Clinical Trials Market
Global Antibiotics Market
You may also like to learn what our experts are sharing in Roots educational series:
Antiviral Drugs Development: Are we Prepared for the Next Viral Pandemic?
Exploring How Artificial Intelligence Is Transforming Digital Pathology
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#nonviraldrugdeliverysystemmarket #nonviraldrugdeliverysystemmarketSize #genedeliverysystems #intracellulardelivery #intracellulardrugdelivery
Exposure to genotoxic and mutagenic compounds can cause mutations in humans, eventually leading to a number of oncological and genetic disorders.
Therefore, testing of genotoxicity / mutagenicity is an essential to assess the safety of products, by ensuring the lack of certain particles that can negatively impact human health. These tests are currently being used across several industries, including healthcare, chemical, cosmetic, agriculture and food.
The financial opportunity within the adeno-associated viral vector market has been analyzed across the following segments:
Type of Assay
In vivo Assays
In vitro Assays
Non-GLP / Screening Assays
Assay / Test Offered
Comet Assays
Micronucleus Assays
Chromosomal Aberration Tests
Genetic Mutation Tests
Other Tests
End User Industry
Chemical Industry
Healthcare Industry
Agriculture Industry
Cosmetic Industry
Other Industries
Geographical Regions
North America
Europe
Asia-Pacific
Latin America
MENA
The research also includes profiles of key players (listed below) engaged in the genotoxicity / mutagenicity testing services market; each profile features an overview of the company, details related to its financial information (if available), service portfolio, recent developments, and an informed future outlook.
Aurigene Pharmaceutical Services
Charles River Laboratories
GLR Laboratories
Labcorp
LSIM Safety Institute
Sai Life Sciences
Syngene
Table of Contents
-
Preface
-
Executive Summary
-
Introduction
-
Market Landscape
-
Benchmarking Analysis
-
Company Profiles
-
Publication Benchmarking Analysis
-
Grants Analysis
-
Partnerships and Collaborations
-
Patent Analysis
-
Market Sizing and Opportunity Analysis
-
Appendix 1: Tabulated Data
-
Appendix 2: List of Companies and Organizations
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/genotoxicity-testing-services-market.html
You may also be interested in the following titles:
Blockchain Technology in Healthcare Market
Long-Acting Drug Delivery Technologies and Services Market
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#GenotoxicityTestingMarket #GenotoxicityTestingMarketSize #mutagenicity #genetictoxicology #genotoxicity testing
Roots Analysis has done a detailed study on Smart Pharmaceutical and Healthcare Labels Market, 2022-2035, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
The current market landscape features the presence of over 90 players engaged in the smart pharmaceutical and healthcare labels domain, worldwide
Over 80 players employ radio frequency identification device-based technology in order to develop cutting-edge labels for a wide range of applications; IoT labels are also gaining traction
Smart labels providers are continuously upgrading their existing portfolio and are seeking investments, as well as expanding their intellectual capital, in order to gain an edge in this competitive industry
More than 400 patents have been granted / filed for smart pharmaceutical and healthcare labels, primarily led by industry players based in North America
A rise in interest in partnerships, in recent past, involving both international and indigenous stakeholders, validate the growing interest in this domain; maximum number of such deals were signed in 2019
Based on the pioneer-migrator-settler map, we have classified the smart label providers into different categories; a selection of pioneers is expected to provide valuable offerings to lead the market in the longer term
The Smart labels market is expected to witness a healthy growth of over 15% in the coming decade; the opportunity is likely to be well distributed across various technologies and different geographical regions
In long term, the majority share of revenues is likely to be driven by players offering smart labels for primary packaging to prevent counterfeiting of drugs
Request a free sample of the report
https://www.rootsanalysis.com/reports/smart-labels-market/request-sample.html
Table of Contents
-
PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Frequently Asked Questions
1.5 Chapter Outlines -
EXECUTIVE SUMMARY
2.1. Chapter Overview -
INTRODUCTION
3.1. Chapter Overview
3.2. Role of Smart Labels in the Healthcare Sector
3.2.1 Types of Smart Labels
3.2.1.1. Radio Frequency Identification Device (RFID)
3.2.1.2. Near-Field Communication (NFC)
3.2.1.3. Internet of Things (IoT)
3.2.2. Need for Smart Labels in the Healthcare Sector
3.2.3. Advantages of Using Smart Labels in Healthcare Sector
3.3. Roadblocks and Challenges Associated with the Adoption of Smart Labels
3.4. Adoption of Smart Labels in the Healthcare Sector
3.4.1. Key Drivers for Adoption of Smart Labels
3.5. Future Outlook
-
MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Smart Pharmaceutical and Healthcare Label Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Technology
4.2.6. Analysis by Company Size and Type of Technology
4.2.7. Analysis by Type of RFID Frequency Band
4.2.8. Analysis by Area(s) of Application
4.2.9. Analysis by Company Size and Area(s) of Application
4.2.10. Analysis by Type of Technology and Area(s) of Application -
COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key parameter
5.3. Methodology
5.3.1. Smart Pharmaceutical and Healthcare Label Providers based in North America
5.3.2. Smart Pharmaceutical and Healthcare Label Providers based in Europe
5.3.3. Smart Pharmaceutical and Healthcare Label Providers based in Asia-Pacific and RoW
5.4. Company Competitiveness Analysis: Benchmarking the Capabilities of Leading Players
- COMPANY PROFILES
6.1. Chapter Overview
6.2. CCL Industries
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Area(s) of Application
6.2.4. Recent Developments and Future Outlook
6.3. Schreiner
6.3.1. Company Overview
6.3.2. Area(s) of Application
6.3.3. Recent Developments and Future Outlook
6.4. Datalogic
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Area(s) of Application
6.4.4. Recent Developments and Future Outlook
6.5. Tadbik
6.5.1. Company Overview
6.5.2. Area(s) of Application
6.5.3. Recent Developments and Future Outlook
6.6. SATO Asia Pacific
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Area(s) of Application
6.6.4. Recent Developments and Future Outlook
6.7. Invengo
6.7.1. Company Overview
6.7.2. Area(s) of Application
6.7.3. Recent Developments and Future Outlook
6.8. Intellhydro Technology
6.8.1. Company Overview
6.8.2. Area(s) of Application
6.8.3. Recent Developments and Future Outlook
6.9. RFiD Discovery
6.9.1. Company Overview
6.9.2. Area(s) of Application
6.9.3. Recent Developments and Future Outlook
6.10. ID Tech Solutions
6.10.1. Company Overview
6.10.2. Area(s) of Application
6.10.3. Recent Developments and Future Outlook
- PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Smart Pharmaceutical and Healthcare Labels: Patent Analysis
7.3.1. Analysis by Publication Year
7.3.2. Analysis by Publication Year and Type of Patent
7.3.3. Analysis by CPC Code
7.3.4. Analysis by Type of Applicant
7.3.5. Analysis by Geography
7.3.6. Analysis by Emerging Focus Areas
7.3.7. Leading Industry Players: Analysis by Number of Patents
7.4. Smart Pharmaceutical and Healthcare Labels: Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics
7.5. Smart Pharmaceutical and Healthcare Labels: Patent Valuation Analysis
-
PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Smart Pharmaceutical and Healthcare Labels: Recent Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Most Active Players: Analysis by Number of Partnerships
8.3.4. Regional Analysis
8.3.4.1. Local and International Agreements
8.3.4.2. Intercontinental and Intracontinental Agreements -
BLUE OCEAN STRATEGY: A STRATEGIC GUIDE FOR START-UPS TO ENTER INTO HIGHLY COMPETITIVE MARKET
9.1. Chapter Overview
9.2. Overview of Blue Ocean Strategy
9.2.1 Red Ocean
9.2.2 Blue Ocean
9.2.3 Comparison of Red Ocean Strategy and Blue Ocean Strategy
9.2.4. Smart Pharmaceuticals and Healthcare Labels: Blue Ocean Strategy and Shift Tools
9.2.4.1. Value Innovation
9.2.4.2. Strategy Canvas
9.2.4.3. Four Action Framework
9.2.4.4. Eliminate-Raise-Reduce-Create (ERRC) Grid
9.2.4.5. Six Path Framework
9.2.4.6. Pioneer-Migrator-Settler (PMS) Map
9.2.4.7. Three Tiers of Noncustomers
9.2.4.8. Sequence of Blue Ocean Strategy
9.2.4.9. Buyer Utility Map
9.2.4.10. The Price Corridor of the Mass
9.2.4.11. Four Hurdles to Strategy Execution
9.2.4.12. Tipping Point Leadership
9.2.4.13. Fair Process
9.3. Concluding Remarks
- MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. Global Smart Pharmaceutical and Healthcare Labels Market, 2022-2035
10.4. Smart Pharmaceutical and Healthcare Labels Market: Analysis by Type of Technology, 2022, 2028 and 2035
10.4.1. Smart Pharmaceutical and Healthcare Labels Market for RFID, 2022-2035
10.4.2. Smart Pharmaceutical and Healthcare Labels Market for NFC, 2022-2035
10.4.3. Smart Pharmaceutical and Healthcare Labels Market for Other Technologies, 2022-2035
10.5. Smart Pharmaceutical and Healthcare Labels Market: Analysis by Type of Packaging, 2022-2035
10.5.1. Smart Pharmaceutical and Healthcare Labels Market: Analysis by Type of Primary Packaging, 2022, 2028 and 2035
10.5.1.1. Smart Pharmaceutical and Healthcare Labels Market for Vials, 2022-2035
10.5.1.2. Smart Pharmaceutical and Healthcare Labels Market for Syringes, 2022-2035
10.5.1.3. Smart Pharmaceutical and Healthcare Labels Market for Cartridges, 2022-2035
10.5.1.4. Smart Pharmaceutical and Healthcare Labels Market for Ampoules, 2022-2035
10.5.1.5. Smart Pharmaceutical and Healthcare Labels Market for Bottles, 2022-2035
10.5.1.6. Smart Pharmaceutical and Healthcare Labels Market for Blister Packs, 2022-2035
10.5.2. Smart Pharmaceutical and Healthcare Labels Market: Analysis by Type of Secondary Packaging, 2022, 2028 and 2035
10.5.2.1. Smart Pharmaceutical and Healthcare Labels Market for Boxes, 2022-2035
10.5.2.2. Smart Pharmaceutical and Healthcare Labels Market for Cartons, 2022-2035
10.5.2.3. Smart Pharmaceutical and Healthcare Labels Market for Pouches, 2022-2035
10.6. Smart Pharmaceutical and Healthcare Labels Market: Analysis by Geography, 2022and 2035
10.6.1. Smart Pharmaceutical and Healthcare Labels Market in North America, 2022-2035
10.6.2. Smart Pharmaceutical and Healthcare Labels Market in Europe, 2022-2035
10.6.3. Smart Pharmaceutical and Healthcare Labels Market in Asia-Pacific, 2022-2035
10.6.4. Smart Pharmaceutical and Healthcare Labels Market in MENA, 2022-2035
10.6.5. Smart Pharmaceutical and Healthcare Labels Market in Latin America, 2022-2035
-
SWOT ANALYSIS
11.1. Chapter Overview
11.2. Strengths
11.3. Weaknesses
11.4. Opportunities
11.5. Threats
11.6. Comparison of SWOT Factors -
CONCLUDING REMARKS
-
APPENDIX I: TABULATED DATA
-
APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/smart-labels-market.html
You may also be interested in the following titles: Oral Solid Dosage Manufacturing Market
Lipid Nanoparticles in Drug Delivery
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#SmartLabelsMarket #SmartLabelsMarketGrowth #HealthcareLabels #SmartLabels #NFC
Owing to the technical and operational challenges associated with the in-house viral clearance and testing procedures, players in the biopharmaceutical industry are increasingly relying on the viral clearance and testing service providers
Roots Analysis has announced the addition of “Viral Clearance and Testing Services Market, 2023 – 2035” report to its list of offerings
The report features an extensive study on the current landscape and the likely future potential of viral clearance and testing services market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:
A general overview of the viral clearance and testing studies, highlighting details on viral contamination in biologics and the need for viral clearance and testing.
A detailed assessment of the overall market landscape of the companies offering viral clearance and testing services, based on several relevant parameters.
A detailed competitiveness analysis of viral clearance and testing service providers based in North America, Europe and Asia-Pacific.
Tabulated profiles of key players based in North America, Europe and Asia-Pacific that are engaged in providing services related to viral clearance and testing (shortlisted based on strength of service portfolio).
An in-depth analysis of various patents that have been filed / granted for viral clearance and testing, since 2017, based on various relevant parameters.
A detailed analysis of recent developments taking place in this domain.
The financial opportunity within the viral clearance and testing services market has been analyzed across the following segments:
Scale of Operation
Discovery Phase
Preclinical Phase
Clinical Phase
Method of Viral Clearance and Viral Testing
Viral Detection
Viral Inactivation
Viral Removal
End-User
Biotechnology and Pharmaceutical Companies
Academic / Research Institutes
Key Geographical Regions
North America
Europe
Asia-Pacific
Rest of the World
Key Companies covered in the report
Charles River Laboratories
Eurofins Scientific
Microbac Laboratories
Nelson Labs
Pall Corporation
Syngene International
Texcell
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/viral-clearance-and-testing-services-market.html
You may also be interested in the following titles:
DNA and Gene Cloning Services Market
Lipid Nanoparticles in Drug Delivery
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
#ViralClearanceandViralTestingServicesMarketTrends #ViralClearanceandViralTestingServicesMarketShare #viralinactivation #viraltesting #viralclearance
The present treatment landscape of chronic wound and bone healing is characterized by a variety of unmet needs; tissue engineering-based regeneration products have emerged as a viable therapeutic option, which is capable of catering to the growing demand
Roots Analysis has announced the addition of “Tissue Engineering-based Regeneration Products Market, 2022-2035” report to its list of offerings.
The report features an extensive study on the extensive study of the current landscape and the likely future potential of tissue engineering-based regeneration products market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:
A detailed review of the current market landscape of tissue engineering-based skin regeneration products based on several relevant parameters, such as type of graft, area of application, type of material of scaffold and launch year. In addition, the chapter lists the players providing tissue engineering-based skin regeneration products, along with information on their respective year of establishment, company size, location of headquarters and target market
A detailed review of the current market landscape of tissue engineering based-bone regeneration products based on several relevant parameters, such as type of graft, formulation of product, type of material of scaffold and launch year. In addition, the chapter lists the players providing tissue engineering-based bone regeneration products, along with information on their respective year of establishment, company size, location of headquarters and target market.
An in-depth analysis, highlighting the market trends through six different schematic representations, including [A] a world map representation, highlighting the regional distribution of the various tissue engineering based-regeneration products providers, [B] a 4D bubble analysis comparing the key players engaged in this domain, based on several relevant parameters (such as year of establishment, company size, number of tissue engineering based-regeneration products offered and region), [C] an insightful spider web representation of tissue engineering based-regeneration products (based on type of graft and area of application), [D] a horizontal stacked bar chart representation presenting the distribution of tissue engineering based-regeneration products providers (based on area of application and material of scaffold), [E] a vertical stacked bar chart representation of tissue engineering-based regeneration products (distribution by product formulation and type of graft) and [F] a vertical stack bar chart representation of tissue engineering based-regeneration products (distribution by region and type of market).
An insightful competitiveness analysis of players engaged in the development of tissue engineering-based regeneration products, based on several relevant parameters, such as years of experience, portfolio strength and funding activity.
Elaborate profiles of prominent players that are currently engaged in offering tissue engineering-based regeneration products. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives). Additionally, the chapter includes company’s tissue regeneration product portfolio, details related to its recent developments and an informed future outlook.
An analysis of the various partnerships that have been inked between several stakeholders in the domain of tissue engineering-based regeneration products, during the period 2017-2022, covering various type of partnership along with analysis on recent investments during the period 2018 and 2022 (till the time of analysis). Further, it includes analysis of other recent initiatives taken by various stakeholders engaged in this domain.
An insightful analysis on filed / granted patents focused on tissue engineering-based regeneration products, during the period 2000-2022 (till the month when the research / analysis was conducted).
The analysis highlights key details and trends associated with these patents, including patent type, publication year, geographical location, assigned CPC symbol, emerging focus area, type of applicant and leading industry / non-industry players. It also includes a patent benchmarking analysis and a detailed valuation analysis.
An analysis that provides information on more than 750 grants that were awarded to various research institutes engaged in studies related to tissue engineering-based regeneration products, during the period 2018 and 2022 (till the time of analysis). The analysis also highlights important parameters associated with grants, The analysis also highlights important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, administration institute center, funding institute center, funding mechanism, spending categorization, grant type, responsible study section, focus area, type of recipient organization and prominent program officers.
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for tissue engineering-based regeneration products market for the next 13 years. Additionally, it features market size projections for the tissue engineering-based regeneration products market, wherein both the current and upcoming opportunity is segmented across [A] area of application, [B] type of graft [C] key geographies. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
By 2035, financial opportunity within the tissue engineering-based regeneration devices has been analyzed across the following segments:
Area of Application
Bone Healing
Burn Healing
Wound Healing
Surgical Healing
Others
Type of Graft
Allografts
Autografts
Xenografts
Key Geographical Regions
North America
Europe
Asia
Latin America
Middle East and North Africa
Rest of the World
Key Companies covered in the report
AlloSource
Bio-Tissue
Integra LifeSciences
MiMedx
Organogenesis
Smith+Nephew
Tissue Regenix
VIVEX Biologics
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/tissue-engineering-market.html
You may also be interested in the following titles:
Gene Switch Market
Digital Biomanufacturing Market
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Owing to the intricacies associated with the manufacturing processes, requirement of advanced production facilities and the growing demand for cell therapy products, developers are actively outsourcing certain manufacturing operations and automation technologies, in addition to expanding their in-house capabilities.
The financial opportunity associated with cell therapy manufacturing market has been analyzed across the following segments:
Type of Cell Therapy
T cell therapies
Dendritic cell therapies
NK cell therapies
Stem cell therapies
Source of Cell
Autologous
Allogeneic
Scale of Operation
Clinical
Commercial
Purpose of Manufacturing
In-house Manufacturing
Contract Manufacturing
Geographical Regions
North America
Europe
Asia Pacific
Rest of the World
The Cell Therapy Manufacturing Market (5th Edition), 2022-2035 report features the following companies, which we identified to be key players in this domain:
AGC Biologics
BioNTech Innovative Manufacturing Services
Cell and Gene Therapy Catapult
Cell Therapies
Center for Cell and Gene Therapy, Baylor College of Medicine
Center for Cell Manufacturing Ireland, National University of Ireland
Charles River Laboratories
Clinical Cell and Vaccine Production Facility, University of Pennsylvania
FUJIFILM Cellular Dynamics
Guy’s and St. Thomas GMP Facility, Guy’s Hospital
KBI Biopharma
Laboratory for Cell and Gene Medicine, Stanford University
Lonza
MEDINET
Minaris Regenerative Medicine
Molecular and Cellular Therapeutics, University of Minnesota
Newcastle Cellular Therapies Facility, Newcastle University
Nikon CeLL innovation
Rayne Cell Therapy Suite, King’s College London
RoslinCT
Scottish National Blood Transfusion Service, Scottish Centre of Regenerative Medicine
Sydney Cell and Gene Therapy
Thermofisher Scientific
WuXi AppTec
Table of Contents
-
Preface
-
Executive Summary
-
Introduction
-
Market Overview
-
Regulatory Landscape
-
Roadmaps for Overcoming Challenges
-
Automation Technologies for Cell Therapy Manufacturing
-
Profiles: Industry Players
-
Profiles: Non-Industry Players
-
Role of Non-Profit Organizations
-
Clinical Trial Analysis
-
Partnerships and Collaborations
-
Recent Expansions
-
Big Pharma Initiatives
-
Capacity Analysis
-
Demand Analysis
-
Cost Price Analysis
-
Make Versus Buy Decision Making Framework
-
Total Cost of Ownership
-
Market Sizing and Opportunity Analysis
-
Key Insights
-
SWOT Analysis
-
Concluding Remarks
-
Survey Analysis
-
Interview Transcripts
-
Appendix 1: Tabulated Data
-
Appendix 2: List of Companies and Organizations
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html
You may also be interested in the following titles:
Conjugation and Labeling Services Market
Bispecific Antibodies Market
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com